Ignite Creation Date:
2025-12-25 @ 12:06 AM
Ignite Modification Date:
2025-12-25 @ 10:05 PM
Study NCT ID:
NCT05514158
Status:
RECRUITING
Last Update Posted:
2023-12-18
First Post:
2022-08-04
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)
Sponsor:
RemeGen Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-09-28
Start Date Type:
ACTUAL
Primary Completion Date:
2024-05-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-09-30
Completion Date Type:
ESTIMATED
First Submit Date:
2022-08-04
First Submit QC Date:
None
Study First Post Date:
2022-08-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-12-15
Last Update Post Date:
2023-12-18
Last Update Post Date Type:
ACTUAL